<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Nuvalent Inc — News on 6ix</title>
<link>https://6ix.com/company/nuvalent-inc</link>
<description>Latest news and press releases for Nuvalent Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Tue, 21 Apr 2026 04:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/nuvalent-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835a41b78dffbe2df10a820.webp</url>
<title>Nuvalent Inc</title>
<link>https://6ix.com/company/nuvalent-inc</link>
</image>
<item>
<title>Nuvalent to Present Pivotal Data from ALKOVE-1 Trial of Neladalkib in TKI Pre-treated Advanced ALK-positive NSCLC at the 2026 American Society of Clinical Oncology Annual Meeting</title>
<link>https://6ix.com/company/nuvalent-inc/news/nuvalent-to-present-pivotal-data-from-alkove-1-trial-of-neladalkib-in-tki-pre-treated-advanced-alk-positive-nsclc-at-the-2026-american-society-of-clinical-oncology-annual-meeting</link>
<guid isPermaLink="true">https://6ix.com/company/nuvalent-inc/news/nuvalent-to-present-pivotal-data-from-alkove-1-trial-of-neladalkib-in-tki-pre-treated-advanced-alk-positive-nsclc-at-the-2026-american-society-of-clinical-oncology-annual-meeting</guid>
<pubDate>Tue, 21 Apr 2026 04:00:00 GMT</pubDate>
<description>Company to also present preliminary data for zidesamtinib in advanced ROS1-positive solid tumors outside of NSCLC from the global ARROS-1 trial CAMBRIDGE,</description>
</item>
<item>
<title>New Clinical and Preclinical Data for Investigational Candidate Zidesamtinib Presented at AACR Annual Meeting 2026</title>
<link>https://6ix.com/company/nuvalent-inc/news/new-clinical-and-preclinical-data-for-investigational-candidate-zidesamtinib-presented-at-aacr-annual-meeting-2026</link>
<guid isPermaLink="true">https://6ix.com/company/nuvalent-inc/news/new-clinical-and-preclinical-data-for-investigational-candidate-zidesamtinib-presented-at-aacr-annual-meeting-2026</guid>
<pubDate>Fri, 17 Apr 2026 20:01:00 GMT</pubDate>
<description>Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced new clinical and preclinical data for zidesamtinib, an investigational ROS1-selective inhibitor, to be presented during poster sessions at the American Association for Cancer Research (AACR) Annual Meeting 2026 being held April 17-22 in San Diego.</description>
</item>
<item>
<title>Nuvalent Announces Submission of New Drug Application to FDA for Neladalkib in TKI Pre-treated Advanced ALK-positive NSCLC</title>
<link>https://6ix.com/company/nuvalent-inc/news/nuvalent-announces-submission-of-new-drug-application-to-fda-for-neladalkib-in-tki-pre-treated-advanced-alk-positive-nsclc</link>
<guid isPermaLink="true">https://6ix.com/company/nuvalent-inc/news/nuvalent-announces-submission-of-new-drug-application-to-fda-for-neladalkib-in-tki-pre-treated-advanced-alk-positive-nsclc</guid>
<pubDate>Tue, 07 Apr 2026 04:00:00 GMT</pubDate>
<description>New Drug Application (NDA) based on data in TKI pre-treated patients from the global ALKOVE-1 Phase 1/2 clinical trialCAMBRIDGE, Mass., April 7, 2026</description>
</item>
<item>
<title>Nuvalent to Present New Preclinical and Clinical Data for Zidesamtinib, an Investigational ROS1-Selective Inhibitor, at AACR Annual Meeting 2026</title>
<link>https://6ix.com/company/nuvalent-inc/news/nuvalent-to-present-new-preclinical-and-clinical-data-for-zidesamtinib-an-investigational-ros1-selective-inhibitor-at-aacr-annual-meeting-2026-1</link>
<guid isPermaLink="true">https://6ix.com/company/nuvalent-inc/news/nuvalent-to-present-new-preclinical-and-clinical-data-for-zidesamtinib-an-investigational-ros1-selective-inhibitor-at-aacr-annual-meeting-2026-1</guid>
<pubDate>Tue, 17 Mar 2026 04:00:00 GMT</pubDate>
<description>CAMBRIDGE, Mass., March 17, 2026 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely</description>
</item>
<item>
<title>Nuvalent Outlines Recent Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports Fourth Quarter and Full Year 2025 Financial Results</title>
<link>https://6ix.com/company/nuvalent-inc/news/nuvalent-outlines-recent-pipeline-progress-reiterates-key-anticipated-milestones-and-reports-fourth-quarter-and-full-year-2025-financial-results</link>
<guid isPermaLink="true">https://6ix.com/company/nuvalent-inc/news/nuvalent-outlines-recent-pipeline-progress-reiterates-key-anticipated-milestones-and-reports-fourth-quarter-and-full-year-2025-financial-results</guid>
<pubDate>Thu, 26 Feb 2026 11:30:00 GMT</pubDate>
<description>Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today outlined pipeline progress, reiterated key anticipated milestones, and reported fourth quarter and full year 2025 financial results.</description>
</item>
<item>
<title>Nuvalent to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026</title>
<link>https://6ix.com/company/nuvalent-inc/news/nuvalent-participate-guggenheim-emerging-outlook-113000265</link>
<guid isPermaLink="true">https://6ix.com/company/nuvalent-inc/news/nuvalent-participate-guggenheim-emerging-outlook-113000265</guid>
<pubDate>Thu, 05 Feb 2026 11:30:00 GMT</pubDate>
<description>Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced that James Porter, Ph.D., Chief Executive Officer, and Alexandra Balcom, Chief Financial Officer, will participate in a fireside chat during the Guggenheim Emerging Outlook: Biotech Summit 2026 on Thursday, February 12, 2026, at 1:30 p.m. ET in NYC.</description>
</item>
<item>
<title>Nuvalent Announces OnTarget 2026 Operating Plan Progress and Outlines Key Anticipated 2026 Milestones</title>
<link>https://6ix.com/company/nuvalent-inc/news/nuvalent-announces-ontarget-2026-operating-113000193</link>
<guid isPermaLink="true">https://6ix.com/company/nuvalent-inc/news/nuvalent-announces-ontarget-2026-operating-113000193</guid>
<pubDate>Mon, 12 Jan 2026 11:30:00 GMT</pubDate>
<description>Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today highlighted pipeline progress and outlined key anticipated milestones towards its first potential U.S. commercial launch under its "OnTarget 2026" operating plan.</description>
</item>
<item>
<title>Nuvalent to Present at the 44th Annual J.P. Morgan Healthcare Conference</title>
<link>https://6ix.com/company/nuvalent-inc/news/nuvalent-present-44th-annual-jp-morgan-healthcare-conference-2025-12-22</link>
<guid isPermaLink="true">https://6ix.com/company/nuvalent-inc/news/nuvalent-present-44th-annual-jp-morgan-healthcare-conference-2025-12-22</guid>
<pubDate>Mon, 22 Dec 2025 05:00:00 GMT</pubDate>
<description>CAMBRIDGE, Mass., Dec. 22, 2025 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely</description>
</item>
<item>
<title>Nuvalent Appoints Ron Squarer to Board of Directors</title>
<link>https://6ix.com/company/nuvalent-inc/news/nuvalent-appoints-ron-squarer-board-directors-2025-12-10</link>
<guid isPermaLink="true">https://6ix.com/company/nuvalent-inc/news/nuvalent-appoints-ron-squarer-board-directors-2025-12-10</guid>
<pubDate>Wed, 10 Dec 2025 05:00:00 GMT</pubDate>
<description>CAMBRIDGE, Mass., Dec. 10, 2025 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely</description>
</item>
<item>
<title>Nuvalent to Participate in the Piper Sandler 37th Annual Healthcare Conference</title>
<link>https://6ix.com/company/nuvalent-inc/news/nuvalent-participate-piper-sandler-37th-annual-healthcare-conference-2025-11-26</link>
<guid isPermaLink="true">https://6ix.com/company/nuvalent-inc/news/nuvalent-participate-piper-sandler-37th-annual-healthcare-conference-2025-11-26</guid>
<pubDate>Wed, 26 Nov 2025 05:00:00 GMT</pubDate>
<description>CAMBRIDGE, Mass., Nov. 26, 2025 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely</description>
</item>
<item>
<title>Nuvalent Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares from Selling Stockholders</title>
<link>https://6ix.com/company/nuvalent-inc/news/nuvalent-announces-closing-public-offering-common-stock-and-full-exercise</link>
<guid isPermaLink="true">https://6ix.com/company/nuvalent-inc/news/nuvalent-announces-closing-public-offering-common-stock-and-full-exercise</guid>
<pubDate>Mon, 24 Nov 2025 05:00:00 GMT</pubDate>
<description>CAMBRIDGE, Mass., Nov. 24, 2025 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely</description>
</item>
<item>
<title>Nuvalent Announces FDA Acceptance of New Drug Application for Zidesamtinib for the Treatment of TKI Pre-treated Patients with Advanced ROS1-positive NSCLC</title>
<link>https://6ix.com/company/nuvalent-inc/news/nuvalent-announces-fda-acceptance-new-drug-application-zidesamtinib-treatment-tki-pre</link>
<guid isPermaLink="true">https://6ix.com/company/nuvalent-inc/news/nuvalent-announces-fda-acceptance-new-drug-application-zidesamtinib-treatment-tki-pre</guid>
<pubDate>Wed, 19 Nov 2025 05:00:00 GMT</pubDate>
<description>NDA based on data from global ARROS-1 Phase 1/2 clinical trial FDA assigns PDUFA target action date of September 18, 2026 CAMBRIDGE, Mass., Nov. 19, 2025</description>
</item>
<item>
<title>Nuvalent Announces Pricing of Public Offering of Common Stock</title>
<link>https://6ix.com/company/nuvalent-inc/news/nuvalent-announces-pricing-public-offering-045000030</link>
<guid isPermaLink="true">https://6ix.com/company/nuvalent-inc/news/nuvalent-announces-pricing-public-offering-045000030</guid>
<pubDate>Wed, 19 Nov 2025 04:50:00 GMT</pubDate>
<description>Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced the pricing of an underwritten public offering of shares of Class A common stock at a price to the public of $101.00 per share. Nuvalent is selling 4,950,496 shares in the offering. The gross proceeds to Nuvalent from the offering, before deducting underwriting discounts and commissions and other offering expens</description>
</item>
<item>
<title>Nuvalent Announces Public Offering of Common Stock</title>
<link>https://6ix.com/company/nuvalent-inc/news/nuvalent-announces-public-offering-common-stock-2025-11-17</link>
<guid isPermaLink="true">https://6ix.com/company/nuvalent-inc/news/nuvalent-announces-public-offering-common-stock-2025-11-17</guid>
<pubDate>Mon, 17 Nov 2025 05:00:00 GMT</pubDate>
<description>CAMBRIDGE, Mass., Nov. 17, 2025 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely</description>
</item>
<item>
<title>Nuvalent Announces Positive Topline Pivotal Data from ALKOVE-1 Clinical Trial of Neladalkib for TKI Pre-treated Patients with Advanced ALK-positive NSCLC</title>
<link>https://6ix.com/company/nuvalent-inc/news/nuvalent-announces-positive-topline-pivotal-data-alkove-1-clinical-trial-neladalkib</link>
<guid isPermaLink="true">https://6ix.com/company/nuvalent-inc/news/nuvalent-announces-positive-topline-pivotal-data-alkove-1-clinical-trial-neladalkib</guid>
<pubDate>Mon, 17 Nov 2025 05:00:00 GMT</pubDate>
<description>In 253 ALK TKI pre-treated patients, ORR by BICR was 31% (95% CI: 26, 37), with initial estimated durability of response of 64% and 53% at the 12-month and</description>
</item>
<item>
<title>Nuvalent Announces Timing of Topline Pivotal Data for TKI Pre-treated Patients with Advanced ALK-positive NSCLC from ALKOVE-1 Clinical Trial of Neladalkib</title>
<link>https://6ix.com/company/nuvalent-inc/news/nuvalent-announces-timing-topline-pivotal-data-tki-pre-treated-patients-advanced-alk</link>
<guid isPermaLink="true">https://6ix.com/company/nuvalent-inc/news/nuvalent-announces-timing-topline-pivotal-data-tki-pre-treated-patients-advanced-alk</guid>
<pubDate>Fri, 14 Nov 2025 05:00:00 GMT</pubDate>
<description>Company to host webcast and conference call on November 17, 2025 at 8:00am ET CAMBRIDGE, Mass., Nov. 14, 2025 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL),</description>
</item>
<item>
<title>Nuvalent to Present Patient-Reported Outcomes Data from ARROS-1 Trial of ROS1-Selective Inhibitor, Zidesamtinib, at 2025 IASLC ASCO North America Conference on Lung Cancer</title>
<link>https://6ix.com/company/nuvalent-inc/news/nuvalent-present-patient-reported-outcomes-data-arros-1-trial-ros1-selective</link>
<guid isPermaLink="true">https://6ix.com/company/nuvalent-inc/news/nuvalent-present-patient-reported-outcomes-data-arros-1-trial-ros1-selective</guid>
<pubDate>Tue, 04 Nov 2025 05:00:00 GMT</pubDate>
<description>Encore pivotal efficacy and safety data from the ARROS-1 trial also to be presented during poster session CAMBRIDGE, Mass., Nov. 4, 2025 /PRNewswire/ --</description>
</item>
<item>
<title>Nuvalent Highlights Recent Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports Third Quarter 2025 Financial Results</title>
<link>https://6ix.com/company/nuvalent-inc/news/nuvalent-highlights-recent-pipeline-progress-reiterates-key-anticipated-milestones</link>
<guid isPermaLink="true">https://6ix.com/company/nuvalent-inc/news/nuvalent-highlights-recent-pipeline-progress-reiterates-key-anticipated-milestones</guid>
<pubDate>Thu, 30 Oct 2025 04:00:00 GMT</pubDate>
<description>Completed rolling NDA submission for zidesamtinib in TKI pre-treated advanced ROS1-positive NSCLC On track to report topline pivotal data for neladalkib in</description>
</item>
<item>
<title>Nuvalent Presents Preliminary Data for Neladalkib in Advanced ALK-positive Solid Tumors Beyond NSCLC at ESMO 2025</title>
<link>https://6ix.com/company/nuvalent-inc/news/nuvalent-presents-preliminary-data-neladalkib-advanced-alk-positive-solid-tumors</link>
<guid isPermaLink="true">https://6ix.com/company/nuvalent-inc/news/nuvalent-presents-preliminary-data-neladalkib-advanced-alk-positive-solid-tumors</guid>
<pubDate>Sat, 18 Oct 2025 04:00:00 GMT</pubDate>
<description>Encouraging preliminary activity observed across diverse set of advanced ALK-positive solid tumors Global enrollment ongoing for adult and adolescent</description>
</item>
<item>
<title>Nuvalent to Present New Preclinical Data for HER2-Selective Inhibitor, NVL-330, at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics</title>
<link>https://6ix.com/company/nuvalent-inc/news/nuvalent-present-new-preclinical-data-her2-selective-inhibitor-nvl-330-aacr-nci-eortc</link>
<guid isPermaLink="true">https://6ix.com/company/nuvalent-inc/news/nuvalent-present-new-preclinical-data-her2-selective-inhibitor-nvl-330-aacr-nci-eortc</guid>
<pubDate>Mon, 13 Oct 2025 04:00:00 GMT</pubDate>
<description>CAMBRIDGE, Mass., Oct. 13, 2025 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely</description>
</item>
</channel>
</rss>